FLAG Therapeutics
Near-term clinical-stage oncology company developing FLAG-003 for DIPG, a rare and fatal pediatric brain cancer.
What They Do
FLAG Therapeutics develops small-molecule therapeutics for difficult-to-treat cancers. Lead pediatric program is FLAG-003 for diffuse intrinsic pontine glioma (DIPG) and glioblastoma multiforme. Relevant to PHD’s tracking universe because Springhood Ventures lists it as a child-health portfolio company and because rare pediatric disease designations, priority review vouchers, and pediatric oncology financing are strategically relevant to children’s health innovation. Note: this is a clinical-stage therapeutics company, not a digital health or care delivery company, and should not appear in existing market map tiles.
Competitive Position
FLAG Therapeutics is a clinical-stage oncology company rather than a digital health startup. Its strategic relevance to PHD is through the pediatric rare disease and oncology therapeutics lens: rare pediatric disease designations, priority review vouchers, and pediatric oncology financing patterns. Tracked as a Springhood Ventures portfolio company in the child-health innovation universe.
Funding Rounds
No funding rounds on record for this company.